Obinutuzumab With Cytarabine Induction for Transplant-Eligible Mantle Cell Lymphoma
In a phase 2 trial, obinutuzumab added to induction therapy showed promising activity and tolerability for transplant-eligible mantle cell lymphoma.
Non-Hodgkin Lymphoma
New Analysis of the Tumor Microenvironment Reveals 3 Subtypes in Large B-Cell Lymphoma of the Brain
The signaling pathways detected may shed light on new treatment strategies.
Lisocabtagene Maraleucel for Relapsed/Refractory Large B-Cell Lymphomas
Investigators assessed safety and efficacy outcomes of lisocabtagene maraleucel in patients with relapsed or refractory large B-cell lymphoma.
Recall of Specific Types of Breast Implants and Tissue Expanders Has Far-Reaching Impact on Patients With Breast Cancer
In Japan, insurance coverage for breast implantation is limited to procedures using Allergen-manufactured products.
Follicular Lymphoma: Interactions With Surrounding Cells to Identify Therapeutic Targets
Characterizing gene expression profiles of FL cells from intrafollicular and extrafollicular regions may help to identify future therapeutic targets.
Hepatosplenic T-cell Lymphoma: Recent Progress and Future Considerations
Researchers reviewed the clinical/pathologic aspects of HSTCL and summarized the latest molecular studies and potential novel therapeutic targets.
Managing Skin Flare Reactions in Patients Receiving Mogamulizumab for Cutaneous T-cell Lymphoma
Using a grading system for skin flare reactions increases potential for continuing administration of mogamulizumab despite the occurrence of this adverse effect.
Waldenström Macroglobulinemia Treated With Ixazomib Combination Therapy: Long-Term Follow Up
Investigators measured ixazomib, dexamethasone, and rituximab combination treatment among patients with treatment-naive Waldenström macroglobulinemia.
2021 Update on Diagnosis, Risk Stratification, and Management of Cutaneous B-Cell Lymphomas
Researchers assessed diagnosis, risk-stratification, and management of 3 distinct subgroups of primary cutaneous lymphomas.
Targeted Therapy for Non-Hodgkin Lymphoma: Current Progress and Future Plans
Novel immunotherapies and small molecule pathway inhibitors are transforming the standard of care for some of the most challenging lymphoma subtypes.
- Loading...
Loading...
Next post in Lymphoma
Loading... 
Loading...